A person’s immune response to variants of SARS-CoV-2, the virus that causes COVID-19, depends on their previous exposure – and differences in the focus of immune responses will help scientists understand how to optimise vaccines in the future to provide broad protection.
Oramed and HTIT to form joint venture for oral drug products
The JV will commence a Phase III clinical trial of oral insulin in the US. Credit: Okrasiuk / Shutterstock.com Oramed Pharmaceuticals and Hefei Tianhui Biotech
August 3, 2023